First, to confirm the effect of the IKKβ inhibitor BAY651942 [51] on cancer-related EMT, we tested the drug on two well-established non-small cell lung cancer lines, A549 and H1299, which have been shown to have high basal levels of NF-κB activity [52,53]. Here, NFKB1 is linked to non-small cell lung carcinoma.